| 17-AAG |
HSp90 inhibitor |
Kosan Bioscience |
I |
| ABJ879 |
Microtubular stabilizer |
Novartis |
I |
| ABT-492 |
Antimicrobial |
Abbott Laboratories |
I |
| ABT-510 |
Angiogenesis inhibitor |
Abbott Laboratories |
II |
| ABT-737 |
Anti Bcl2 protein |
Abbott Laboratories |
II |
| ABT-751 |
Microtubulin inhibitor |
Abbott Laboratories |
II |
| ABT-869 |
TKI VEGFR, PDGFR inhibitor |
Abbott Laboratories |
I |
| AEE788 |
TKI VEGFR, PDGFR inhibitor |
Novartis |
I |
| AG-2037 |
Antifolate inhibitor |
Pfizer |
II |
| AG-13736 |
TKI VEGF |
Pfizer |
II |
| AI-128 (paclitaxel) |
Taxane |
Acusphere |
I |
| Albuleukin |
Long acting IL-2 |
Human Genome |
I |
| AMG 706 |
MKI VEGFR, PDGFR, Kit, RET |
Amgen |
I |
| AP23573 |
mTor inihibitor |
Ariad |
I |
| AP5280 |
Polymer platinate |
Access Oncology |
I |
| Apoluzimab (remitogen) |
MoAb |
Protein Design Lab |
I |
| ATN-161 |
Integrin antagonist |
Attenuon |
I |
| AVE-0005 |
VEGF-trap |
Regeneron Aventis |
I |
| AVE-8062 |
Combreastatin derivative |
Regeneron Aventis |
I |
| ATRA-IV |
Liposomal retinoic acid |
Serono |
II |
| AZD0530 |
Src/Abl kinase inhibitor |
AstraZeneca |
I |
| AZD2171 |
TKI VEGFR inhibitor |
AstraZeneca |
I |
| AZD3409 |
Prenyl transferase |
AstraZeneca |
I |
| AZD5438 |
CDK inhibitor |
AstraZeneca |
I |
| AZD6474 |
Anti angiogenic |
AstraZeneca |
II |
| BAY 43-9006 (sorafenib) |
MKI VEGFR-2, VEGFR-3, PDGFR-B, RAF, Kit, FLT-3, RET |
Bayer Pharmaceuticals Onyx Pharmaceuticals |
I |
| Benefin |
Anti angiogensis |
Lane Labs-USA |
II |
| BMS184476 |
Taxane |
Bristol-Myers Squibb |
II |
| Cancer Vaccine |
Vaccine |
Vical |
I |
| CDP-860 |
Pegylated MoAb |
Cell Tech |
II |
| CC8490 |
Benzozypran |
Celgene |
I |
| CEP7055 |
VEGFR inhibitor |
Sanofi/Adventis |
I |
| CI-1003 (canertinib) |
TKI EGFR inhibitor |
Pfizer |
II |
| Clofarabine |
Nucleoside analog of cytosine |
Ilex |
I |
| Cotara |
Radioimmune therapy |
Perigrine |
I |
| CP-461 |
Sulindac analog |
Cell Pathways |
II |
| CP547632 |
TGI VEGFR inhibitor |
OSI |
II |
| CP868596 |
TKI PDGF inhibitor |
OSI |
I |
| Diflomotecan |
Camptothecin analogue |
Roche |
II |
| DJ927 |
Oral Taxane |
Dauchi |
II |
| DX-8951F (exatecan mesylate) |
Topoisomerase I inhibitor |
Daiichi Pharmaceutical |
III |
| E7386 |
Macrolytic ketone analog |
Eisai |
I |
| E7820 |
Integrina 2 inhibitor |
Eisai |
I |
| Endovion (NS3728) |
Anti-angionenesis VRAC ion channel inhibitor |
Neuro Research |
I |
| Epitholone D (EPO906) |
Microtubule stabilizer |
Novartis |
II |
| Ethynylcytidine |
RNA polymerase inhibitor |
GlaxoSmithKline |
II |
| GEM231 |
Antisense |
Hybridon Inc. |
I |
| Genasense |
Antisense |
Genta Aventis |
I |
| Genexol-PM |
Cremaphor free taxane |
Samyang Corporation |
I |
| Gimatecan |
Topoisomerase I inhibitor |
Novartis |
II |
| GEM 231 |
Antisense therapy |
Hybridon |
I |
| Genasense (oblimersen) |
Antisense |
Genta and Aventis |
II |
| Gleevec (imatinib) |
Tyrosine kinase inhibitor |
Novartis |
II |
| GTI 2040 |
Antisense |
Lorus |
II |
| GW572016 |
EGFR/HER2 kinase inhibitor |
GlaxoSmithKline |
II |
| HMN-214 |
Oral inhibitor of MDR1 |
Biogen Idec |
I |
| INGN241 |
Adenoviral vector |
Introgen |
II |
| IGN 301 |
Anti-idiotypic vaccine |
Ingeneon Ag |
I (epithelia cancer) |
| Inhaled Orathecin (rubitecan) |
Topoisomerase Inhibitor |
Supergen |
II |
| Irofulven |
Acykfukvene |
MGI |
I |
| JNK 401 |
JNK inhibitor |
Celgene |
I |
| LAQ824 |
HDAC inhibitor |
Novartis |
I |
| LBH589 |
HDAC inhibitor |
Novartis |
I |
| LEP ETU (paclitaxel) |
Taxane |
NeoPharm |
I |
| Liposome Encapsulated Mitoxantrone |
Antitumor antibiotic |
NeoPharm |
I |
| Lurtotecan |
Topoisomerase inhibitor |
OSI Pharmaceuticals |
II |
| MAB 2C4 |
Monoclonal antibody |
Roche |
II |
| M40403 (superoxide dismutase) |
Antioxidant |
Metaphore Pharm |
I |
| MLN 576 |
Topoisomerase I/II inhibitor |
Millennium |
I |
| MLN 944 |
DNA/RNA target |
Millennium |
I |
| Navelbine Oral (vinorelbine) |
Vinca alkaloid |
GlaxoSmithKline |
III |
| NBI-3001 |
IL4 pseudomonas enndotoxin |
Neurocrine Bioscience |
I |
| Octreother (octreotide) |
Somatostatin analog |
Novartis |
II |
| Oncomyc-NG |
Antisense |
AVI Biopharma |
I |
| Onco TCS (vincristine) |
Antimicrotubule |
Inex Pharmaceuticals |
II |
| OSI07836 |
Gemzar analog |
OSI |
I |
| PEG-Interferon (peginterferon alfa-2b) |
Interferon |
Schering-Plough |
II |
| Perifosine (KRX041) |
AKT inhibitor |
Keryx BioPharm |
II |
| Promune |
Toll like receptor 9 agonist |
Coley Pharmaceutical |
I |
| PX-12 |
Trx 1 inhibitor |
ProIX Pharm |
I |
| RAD001 (everolimus) |
mTor inhibitor |
Novartis |
II |
| R1536 |
polyketide |
Roche |
II |
| SSR 125329 |
Peripheral sigma ligand |
Sanofi/Aventis |
I |
| Taxotere (docetaxel) |
Taxoid |
Aventis |
II |
| Temodar (temozolomide) |
Alkylating agent |
Schering-Plough |
II |
| Tempostatin |
Selective inhibitor of stromal cell activation |
Collgard Biopharma |
I |
| TG1024 (adenovirus IL2) |
Vaccine |
Transgene |
I/II |
| TLK 286 (telcyta) |
Glutathione |
Telik |
I |
| TNFerade |
Tumor necrosis factor alpha gene |
GenVec |
II |
| TRAIL –R2 |
MoAb |
Human Genome |
I |
| VX-853 (timcodar) |
MDR inhibitor |
Vertex |
I |
| Velcade (bortezomib) |
Proteosome inhibitor |
Millennium |
I |
| ZD0473 |
Platinum |
Astra Zeneca |
II |
| ZD4054 |
ETA receptor antagonist |
Astra Zeneca |
II |
| ZD6474 |
TKI VEGF2 inhibitor |
Astra Zeneca |
II |
Patient Home
Meeting Calendar
